Literature DB >> 8406453

A homoallelic Gly317-->Asp mutation in ALPL causes the perinatal (lethal) form of hypophosphatasia in Canadian mennonites.

C R Greenberg1, C L Taylor, J C Haworth, L E Seargeant, S Philipps, B Triggs-Raine, B N Chodirker.   

Abstract

We have discovered a single homoallelic nucleotide substitution as the putative cause of the perinatal (lethal) form of hypophosphatasia in Canadian Mennonites. Previous linkage and haplotype analysis in this population suggested that a single mutational event was responsible for this autosomal recessive form of hypophosphatasia. The mutation is a guanosine-to-adenosine substitution at nucleotide position 1177 in exon 10 of the tissue nonspecific (liver/bone/kidney) alkaline phosphatase gene. This Gly317-->Asp mutation segregates exclusively with the heterozygote phenotype we previously assigned by biochemical testing (maximum combined lod score of 18.24 at theta = 0.00). This putative disease-causing mutation has not been described in controls nor in other non-Mennonite probands with both lethal and nonlethal forms of hypophosphatasia studied to date. This Gly317-->Asp mutation changes a polar glycine to an acidic aspartate at amino acid position 317 within the highly conserved active site region of the 507-amino-acid polypeptide. Carrier screening for this lethal mutation in our high-risk population is now feasible.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8406453     DOI: 10.1006/geno.1993.1305

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  28 in total

1.  Possible interference between tissue-non-specific alkaline phosphatase with an Arg54-->Cys substitution and acounterpart with an Asp277-->Ala substitution found in a compound heterozygote associated with severe hypophosphatasia.

Authors:  M Fukushi-Irié; M Ito; Y Amaya; N Amizuka; H Ozawa; S Omura; Y Ikehara; K Oda
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Molecular evolution of the tissue-nonspecific alkaline phosphatase allows prediction and validation of missense mutations responsible for hypophosphatasia.

Authors:  Jérémie Silvent; Barbara Gasse; Etienne Mornet; Jean-Yves Sire
Journal:  J Biol Chem       Date:  2014-07-14       Impact factor: 5.157

3.  Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia.

Authors:  Christine Hofmann; Hermann Girschick; Etienne Mornet; Doris Schneider; Franz Jakob; Birgit Mentrup
Journal:  Eur J Hum Genet       Date:  2014-02-26       Impact factor: 4.246

4.  Outcome of perinatal hypophosphatasia in manitoba mennonites: a retrospective cohort analysis.

Authors:  Edward C W Leung; Aizeddin A Mhanni; Martin Reed; Michael P Whyte; Hal Landy; Cheryl R Greenberg
Journal:  JIMD Rep       Date:  2013-04-12

5.  ALPL mutations in adults with rheumatologic disorders and low serum alkaline phosphatase activity.

Authors:  Frank Rauch; Ghalib Bardai; Cheryl Rockman-Greenberg
Journal:  J Bone Miner Metab       Date:  2019-02-04       Impact factor: 2.626

6.  Hypophosphatasia - pathophysiology and treatment.

Authors:  José Luis Millán; Horacio Plotkin
Journal:  Actual osteol       Date:  2012-09-01

7.  Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5'-phosphate. Substrate accumulation in carriers of hypophosphatasia corrects during pregnancy.

Authors:  M P Whyte; M Landt; L M Ryan; R A Mulivor; P S Henthorn; K N Fedde; J D Mahuren; S P Coburn
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

8.  A large novel deletion in the APC promoter region causes gene silencing and leads to classical familial adenomatous polyposis in a Manitoba Mennonite kindred.

Authors:  George S Charames; Lily Ramyar; Angela Mitri; Terri Berk; Hong Cheng; Jack Jung; Patricia Bocangel; Bernie Chodirker; Cheryl Greenberg; Elizabeth Spriggs; Bharati Bapat
Journal:  Hum Genet       Date:  2008-11-04       Impact factor: 4.132

9.  Infantile hypophosphatasia secondary to a novel compound heterozygous mutation presenting with pyridoxine-responsive seizures.

Authors:  Dina Belachew; Traci Kazmerski; Ingrid Libman; Amy C Goldstein; Susan T Stevens; Stephanie Deward; Jerry Vockley; Mark A Sperling; Arcangela L Balest
Journal:  JIMD Rep       Date:  2013-03-12

Review 10.  Asfotase Alfa: A Review in Paediatric-Onset Hypophosphatasia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.